RxScorecard offers the first and only tool to assess the value of marketed and pipeline drugs from a payer’s point of view. Faced with increasing market access challenges, manufacturers must strengthen value differentiation for new drugs from a payer perspective to obtain favorable reimbursement. Payers seek an objective, transparent tool to help assess the relative value of emerging and existing therapies, and inform formulary and UM policies.